Hydrogel-Based 3D Model of Patient-Derived Prostate Xenograft Tumors Suitable for Drug Screening

dc.citation.firstpage2040en_US
dc.citation.issueNumber7en_US
dc.citation.journalTitleMolecular Pharmaceuticsen_US
dc.citation.lastpage2050en_US
dc.citation.volumeNumber11en_US
dc.contributor.authorFong, Eliza L.S.en_US
dc.contributor.authorMartinez, Marianeen_US
dc.contributor.authorYang, Junen_US
dc.contributor.authorMikos, Antonios G.en_US
dc.contributor.authorNavone, Nora M.en_US
dc.contributor.authorHarrington, Daniel Antonen_US
dc.contributor.authorFarach-Carson, Mary C.en_US
dc.date.accessioned2015-10-28T19:04:03Zen_US
dc.date.available2015-10-28T19:04:03Zen_US
dc.date.issued2014en_US
dc.description.abstractThe lack of effective therapies for bone metastatic prostate cancer (PCa) underscores the need for accurate models of the disease to enable the discovery of new therapeutic targets and to test drug sensitivities of individual tumors. To this end, the patient-derived xenograft (PDX) PCa model using immunocompromised mice was established to model the disease with greater fidelity than is possible with currently employed cell lines grown on tissue culture plastic. However, poorly adherent PDX tumor cells exhibit low viability in standard culture, making it difficult to manipulate these cells for subsequent controlled mechanistic studies. To overcome this challenge, we encapsulated PDX tumor cells within a three-dimensional hyaluronan-based hydrogel and demonstrated that the hydrogel maintains PDX cell viability with continued native androgen receptor expression. Furthermore, a differential sensitivity to docetaxel, a chemotherapeutic drug, was observed as compared to a traditional PCa cell line. These findings underscore the potential impact of this novel 3D PDX PCa model as a diagnostic platform for rapid drug evaluation and ultimately push personalized medicine toward clinical reality.en_US
dc.identifier.citationFong, Eliza L.S., Martinez, Mariane, Yang, Jun, et al.. "Hydrogel-Based 3D Model of Patient-Derived Prostate Xenograft Tumors Suitable for Drug Screening." <i>Molecular Pharmaceutics,</i> 11, no. 7 (2014) American Chemical Society: ᅠ2040-2050. http://dx.doi.org/10.1021/mp500085p.en_US
dc.identifier.doihttp://dx.doi.org/10.1021/mp500085pen_US
dc.identifier.urihttps://hdl.handle.net/1911/81940en_US
dc.language.isoengen_US
dc.publisherAmerican Chemical Societyen_US
dc.rightsThis is an open access article published under an ACS AuthorChoice License, which permits copying and redistribution of the article or any adaptations for non-commercial purposes.en_US
dc.rights.urihttp://pubs.acs.org/page/policy/authorchoice_termsofuse.htmlen_US
dc.subject.keywordpatient-derived xenograften_US
dc.subject.keywordhydrogelen_US
dc.subject.keywordtumoren_US
dc.subject.keyworddrugen_US
dc.subject.keywordprostate canceren_US
dc.titleHydrogel-Based 3D Model of Patient-Derived Prostate Xenograft Tumors Suitable for Drug Screeningen_US
dc.typeJournal articleen_US
dc.type.dcmiTexten_US
dc.type.publicationpublisher versionen_US
Files
Original bundle
Now showing 1 - 2 of 2
Loading...
Thumbnail Image
Name:
mp500085p.pdf
Size:
2.41 MB
Format:
Adobe Portable Document Format
Description:
Article
Loading...
Thumbnail Image
Name:
mp500085p_si_001.pdf
Size:
292.79 KB
Format:
Adobe Portable Document Format
Description:
Supplementary Information